<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37368329</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2035-8385</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>31</Day></PubDate></JournalIssue><Title>Neurology international</Title><ISOAbbreviation>Neurol Int</ISOAbbreviation></Journal><ArticleTitle>Scientific Rationale for the Treatment of Cognitive Deficits from Long COVID.</ArticleTitle><Pagination><StartPage>725</StartPage><EndPage>742</EndPage><MedlinePgn>725-742</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/neurolint15020045</ELocationID><Abstract><AbstractText>Sustained cognitive deficits are a common and debilitating feature of "long COVID", but currently there are no FDA-approved treatments. The cognitive functions of the dorsolateral prefrontal cortex (dlPFC) are the most consistently afflicted by long COVID, including deficits in working memory, motivation, and executive functioning. COVID-19 infection greatly increases kynurenic acid (KYNA) and glutamate carboxypeptidase II (GCPII) in brain, both of which can be particularly deleterious to PFC function. KYNA blocks both NMDA and nicotinic-alpha-7 receptors, the two receptors required for dlPFC neurotransmission, and GCPII reduces mGluR3 regulation of cAMP-calcium-potassium channel signaling, which weakens dlPFC network connectivity and reduces dlPFC neuronal firing. Two agents approved for other indications may be helpful in restoring dlPFC physiology: the antioxidant N-acetyl cysteine inhibits the production of KYNA, and the &#x3b1;2A-adrenoceptor agonist guanfacine regulates cAMP-calcium-potassium channel signaling in dlPFC and is also anti-inflammatory. Thus, these agents may be helpful in treating the cognitive symptoms of long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fesharaki Zadeh</LastName><ForeName>Arman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departments of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnsten</LastName><ForeName>Amy F T</ForeName><Initials>AFT</Initials><Identifier Source="ORCID">0000-0002-3420-1308</Identifier><AffiliationInfo><Affiliation>Departments of Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departments of Neuroscience, Yale University School of Medicine, New Haven, CT 06510, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG066508</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG061190</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neurol Int</MedlineTA><NlmUniqueID>101551564</NlmUniqueID><ISSNLinking>2035-8385</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">cognitive</Keyword><Keyword MajorTopicYN="N">guanfacine</Keyword><Keyword MajorTopicYN="N">n-acetyl cysteine</Keyword><Keyword MajorTopicYN="N">prefrontal cortex</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>27</Day><Hour>13</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>27</Day><Hour>13</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>27</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37368329</ArticleId><ArticleId IdType="pmc">PMC10303664</ArticleId><ArticleId IdType="doi">10.3390/neurolint15020045</ArticleId><ArticleId IdType="pii">neurolint15020045</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Szczepanski S.M., Knight R.T. Insights into human behavior from lesions to the prefrontal cortex. Neuron. 2014;83:1002&#x2013;1018. doi: 10.1016/j.neuron.2014.08.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.08.011</ArticleId><ArticleId IdType="pmc">PMC4156912</ArticleId><ArticleId IdType="pubmed">25175878</ArticleId></ArticleIdList></Reference><Reference><Citation>Preuss T.M., Wise S.P. Evolution of prefrontal cortex. Neuropsychopharmacology. 2022;47:3&#x2013;19. doi: 10.1038/s41386-021-01076-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-021-01076-5</ArticleId><ArticleId IdType="pmc">PMC8617185</ArticleId><ArticleId IdType="pubmed">34363014</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander L., Wood C.M., Roberts A.C. The ventromedial prefrontal cortex and emotion regulation: Lost in translation? J. Physiol. 2023;601:37&#x2013;50. doi: 10.1113/JP282627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP282627</ArticleId><ArticleId IdType="pmc">PMC10084434</ArticleId><ArticleId IdType="pubmed">35635793</ArticleId></ArticleIdList></Reference><Reference><Citation>Elston G.N., Benavides-Piccione R., Elston A., Zietsch B., Defelipe J., Manger P., Casagrande V., Kaas J.H. Specializations of the granular prefrontal cortex of primates: Implications for cognitive processing. Anat. Rec. A Discov. Mol. Cell. Evol. Biol. 2006;288:26&#x2013;35. doi: 10.1002/ar.a.20278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ar.a.20278</ArticleId><ArticleId IdType="pubmed">16342214</ArticleId></ArticleIdList></Reference><Reference><Citation>Defelipe J. The evolution of the brain, the human nature of cortical circuits, and intellectual creativity. Front. Neuroanat. 2011;5:29. doi: 10.3389/fnana.2011.00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2011.00029</ArticleId><ArticleId IdType="pmc">PMC3098448</ArticleId><ArticleId IdType="pubmed">21647212</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman-Rakic P. Cellular Basis of Working Memory. Neuron. 1995;14:477&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">7695894</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy R., Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb. Cortex. 2006;16:916&#x2013;928. doi: 10.1093/cercor/bhj043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhj043</ArticleId><ArticleId IdType="pubmed">16207933</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman N.P., Robbins T.W. The role of prefrontal cortex in cognitive control and executive function. Neuropsychopharmacology. 2022;47:72&#x2013;89. doi: 10.1038/s41386-021-01132-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-021-01132-0</ArticleId><ArticleId IdType="pmc">PMC8617292</ArticleId><ArticleId IdType="pubmed">34408280</ArticleId></ArticleIdList></Reference><Reference><Citation>Robbins T.W. Dissociating executive functions of the prefrontal cortex. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 1996;351:1463&#x2013;1470. doi: 10.1098/rstb.1996.0131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.1996.0131</ArticleId><ArticleId IdType="pubmed">8941958</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimberg D.Y., Farah M.J. A unified account of cognitive impairments following frontal lobe damage: The role of working memory in complex, organized behavior. J. Exp. Psychol. Gen. 1993;122:411&#x2013;428. doi: 10.1037/0096-3445.122.4.411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0096-3445.122.4.411</ArticleId><ArticleId IdType="pubmed">8263463</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon V., D&#x2019;Esposito M. The role of PFC networks in cognitive control and executive function. Neuropsychopharmacology. 2022;47:90&#x2013;103. doi: 10.1038/s41386-021-01152-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-021-01152-w</ArticleId><ArticleId IdType="pmc">PMC8616903</ArticleId><ArticleId IdType="pubmed">34408276</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolcos F., McCarthy G. Brain systems mediating cognitive interference by emotional distraction. J. Neurosci. 2006;26:2072&#x2013;2079. doi: 10.1523/JNEUROSCI.5042-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5042-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674921</ArticleId><ArticleId IdType="pubmed">16481440</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias E.C., McGinnis T., Smiley J.F., Foxe J.J., Schroeder C.E., Javitt D.C. Changing plans: Neural correlates of executive control in monkey and human frontal cortex. Exp. Brain Res. 2006;174:279&#x2013;291. doi: 10.1007/s00221-006-0444-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00221-006-0444-4</ArticleId><ArticleId IdType="pubmed">16636795</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuster J.M. Prefrontal neurons in networks of executive memory. Brain Res. Bull. 2000;52:331&#x2013;336. doi: 10.1016/S0361-9230(99)00258-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0361-9230(99)00258-0</ArticleId><ArticleId IdType="pubmed">10922510</ArticleId></ArticleIdList></Reference><Reference><Citation>Aron A.R. The neural basis of inhibition in cognitive control. Neuroscientist. 2007;13:214&#x2013;228. doi: 10.1177/1073858407299288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858407299288</ArticleId><ArticleId IdType="pubmed">17519365</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungerleider L.G., Courtney S.M., Haxby J.V. A neural system for human visual working memory. Proc. Natl. Acad. Sci. USA. 1998;95:883&#x2013;890. doi: 10.1073/pnas.95.3.883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.3.883</ArticleId><ArticleId IdType="pmc">PMC33812</ArticleId><ArticleId IdType="pubmed">9448255</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsujimoto S., Genovesio A., Wise S.P. Frontal pole cortex: Encoding ends at the end of the endbrain. Trends Cogn. Sci. 2011;15:169&#x2013;176. doi: 10.1016/j.tics.2011.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2011.02.001</ArticleId><ArticleId IdType="pubmed">21388858</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce M.K.P., Marshall L.G., Banik S.L., Wang J., Xiao D., Bunce J.G., Barbas H. Pathways for Memory, Cognition and Emotional Context: Hippocampal, Subgenual Area 25, and Amygdalar Axons Show Unique Interactions in the Primate Thalamic Reuniens Nucleus. J. Neurosci. 2022;42:1068&#x2013;1089. doi: 10.1523/JNEUROSCI.1724-21.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1724-21.2021</ArticleId><ArticleId IdType="pmc">PMC8824507</ArticleId><ArticleId IdType="pubmed">34903572</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes S.E., Scheinost D., Finnema S.J., Naganawa M., Davis M.T., DellaGioia N., Nabulsi N., Matuskey D., Angarita G.A., Pietrzak R.H., et al. Lower synaptic density is associated with depression severity and network alterations. Nat. Commun. 2019;10:1529. doi: 10.1038/s41467-019-09562-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09562-7</ArticleId><ArticleId IdType="pmc">PMC6449365</ArticleId><ArticleId IdType="pubmed">30948709</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J., Kremer S., Merdji H., Clere-Jehl R., Schenck M., Kummerlen C., Collange O., Boulay C., Fafi-Kremer S., Ohana M., et al. Neurologic Features in Severe SARS-CoV-2 Infection. N. Engl. J. Med. 2020;382:2268&#x2013;2270. doi: 10.1056/NEJMc2008597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2008597</ArticleId><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker J.H., Lin J.J., Doernberg M., Stone K., Navis A., Festa J.R., Wisnivesky J.P. Assessment of Cognitive Function in Patients After COVID-19 Infection. JAMA Netw. Open. 2021;4:e2130645. doi: 10.1001/jamanetworkopen.2021.30645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.30645</ArticleId><ArticleId IdType="pmc">PMC8536953</ArticleId><ArticleId IdType="pubmed">34677597</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmuth J., Barnett T.A., Asken B.M., Kelly J.D., Torres L., Stephens M.L., Greenhouse B., Martin J.N., Chow F.C., Deeks S.G., et al. Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. J. Neurovirol. 2021;27:191&#x2013;195. doi: 10.1007/s13365-021-00954-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00954-4</ArticleId><ArticleId IdType="pmc">PMC7852463</ArticleId><ArticleId IdType="pubmed">33528824</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderlind W.M., Rabinovitz B.B., Miao I.Y., Oberlin L.E., Bueno-Castellano C., Fridman C., Jaywant A., Kanellopoulos D. A systematic review of neuropsychological and psychiatric sequalae of COVID-19: Implications for treatment. Curr. Opin. Psychiatry. 2021;34:420&#x2013;433. doi: 10.1097/YCO.0000000000000713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0000000000000713</ArticleId><ArticleId IdType="pmc">PMC8183238</ArticleId><ArticleId IdType="pubmed">34016818</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A., Trender W., Chamberlain S.R., Jolly A.E., Grant J.E., Patrick F., Mazibuko N., Williams S.C., Barnby J.M., Hellyer P., et al. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021;39:101044. doi: 10.1016/j.eclinm.2021.101044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101044</ArticleId><ArticleId IdType="pmc">PMC8298139</ArticleId><ArticleId IdType="pubmed">34316551</ArticleId></ArticleIdList></Reference><Reference><Citation>Spudich S., Nath A. Nervous system consequences of COVID-19. Science. 2022;375:267&#x2013;269. doi: 10.1126/science.abm2052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm2052</ArticleId><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrottelli A., Sansone N., Giordano G.M., Caporusso E., Giuliani L., Melillo A., Pezzella P., Bucci P., Mucci A., Galderisi S. Cognitive Impairment after Post-Acute COVID-19 Infection: A Systematic Review of the Literature. J. Pers. Med. 2022;12:2070. doi: 10.3390/jpm12122070.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm12122070</ArticleId><ArticleId IdType="pmc">PMC9781311</ArticleId><ArticleId IdType="pubmed">36556290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zawilska J.B., Kuczy&#x144;ska K. Psychiatric and neurological complications of long COVID. J. Psychiatr. Res. 2022;156:349&#x2013;360. doi: 10.1016/j.jpsychires.2022.10.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2022.10.045</ArticleId><ArticleId IdType="pmc">PMC9582925</ArticleId><ArticleId IdType="pubmed">36326545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertuccelli M., Ciringione L., Rubega M., Bisiacchi P., Masiero S., Del Felice A. Cognitive impairment in people with previous COVID-19 infection: A scoping review. Cortex. 2022;154:212&#x2013;230. doi: 10.1016/j.cortex.2022.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cortex.2022.06.002</ArticleId><ArticleId IdType="pmc">PMC9187867</ArticleId><ArticleId IdType="pubmed">35780756</ArticleId></ArticleIdList></Reference><Reference><Citation>Houben S., Bonnech&#xe8;re B. The Impact of COVID-19 Infection on Cognitive Function and the Implication for Rehabilitation: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health. 2022;19:7748. doi: 10.3390/ijerph19137748.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19137748</ArticleId><ArticleId IdType="pmc">PMC9266128</ArticleId><ArticleId IdType="pubmed">35805406</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng N., Zhao Y.-M., Yan W., Li C., Lu Q.-D., Liu L., Ni S.-Y., Mei H., Yuan K., Shi L., et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: Call for research priority and action. Mol. Psychiatry. 2023;28:423&#x2013;433. doi: 10.1038/s41380-022-01614-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01614-7</ArticleId><ArticleId IdType="pmc">PMC9168643</ArticleId><ArticleId IdType="pubmed">35668159</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Ling S., Lui L.M.W., Lee Y., Gill H., Teopiz K.M., Rodrigues N.B., Subramaniapillai M., Di Vincenzo J.D., Cao B., et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten A.F.T., Joyce M.K., Roberts A.C. The Aversive Lens: Stress effects on the prefrontal-cingulate cortical pathways that regulate emotion. Neurosci. Biobehav. Rev. 2022;145:105000. doi: 10.1016/j.neubiorev.2022.105000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2022.105000</ArticleId><ArticleId IdType="pmc">PMC9898199</ArticleId><ArticleId IdType="pubmed">36529312</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera E., P&#xe9;rez-S&#xe1;nchez M.D.C., San Miguel-Abella R., Barrenechea A., Blanco C., Solares L., Gonz&#xe1;lez L., Iza C., Castro I., Nicol&#xe1;s E., et al. Cognitive impairment in young adults with post COVID-19 syndrome. Sci. Rep. 2023;13:6378. doi: 10.1038/s41598-023-32939-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-32939-0</ArticleId><ArticleId IdType="pmc">PMC10113715</ArticleId><ArticleId IdType="pubmed">37076533</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamberini G., Masuccio F.G., Cerrato M., Strazzacappa M., Ferraro D., Solaro C. Previously independent patients with mild-symptomatic COVID-19 are at high risk of developing cognitive impairment but not depression or anxiety. J. Affect. Disord. 2023;324:645&#x2013;651. doi: 10.1016/j.jad.2022.12.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2022.12.100</ArticleId><ArticleId IdType="pmc">PMC9812466</ArticleId><ArticleId IdType="pubmed">36610599</ArticleId></ArticleIdList></Reference><Reference><Citation>Taruffi L., Muccioli L., Mitolo M., Ferri L., Descovich C., Mazzoni S., Michelucci R., Lodi R., Liguori R., Cortelli P., et al. Neurological Manifestations of Long COVID: A Single-Center One-Year Experience. Neuropsychiatr. Dis. Treat. 2023;19:311&#x2013;319. doi: 10.2147/NDT.S387501.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S387501</ArticleId><ArticleId IdType="pmc">PMC9904212</ArticleId><ArticleId IdType="pubmed">36761395</ArticleId></ArticleIdList></Reference><Reference><Citation>He D., Yuan M., Dang W., Bai L., Yang R., Wang J., Ma Y., Liu B., Liu S., Zhang S., et al. Long term neuropsychiatric consequences in COVID-19 survivors: Cognitive impairment and inflammatory underpinnings fifteen months after discharge. Asian J. Psychiatr. 2023;80:103409. doi: 10.1016/j.ajp.2022.103409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajp.2022.103409</ArticleId><ArticleId IdType="pmc">PMC9751007</ArticleId><ArticleId IdType="pubmed">36549172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cysique L.A., Jakabek D., Bracken S.G., Allen-Davidian Y., Heng B., Chow S., Dehhaghi M., Staats Pires A., Darley D.R., Byrne A., et al. Post-acute COVID-19 cognitive impairment and decline uniquely associate with kynurenine pathway activation: A longitudinal observational study. medRxiv. 2022 doi: 10.1101/2022.06.07.22276020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.07.22276020</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiken S., Sittenfeld L., Dridi H., Liu Y., Liu X., Marks A.R. Alzheimer&#x2019;s-like signaling in brains of COVID-19 patients. Alzheimer&#x2019;s Dement. 2022;18:955&#x2013;965. doi: 10.1002/alz.12558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12558</ArticleId><ArticleId IdType="pmc">PMC9011576</ArticleId><ArticleId IdType="pubmed">35112786</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo E., Sansing L.H., Arnsten A.F.T., Datta D. Chronic Stress Weakens Connectivity in the Prefrontal Cortex: Architectural and Molecular Changes. Chronic Stress. 2021;5:24705470211029254. doi: 10.1177/24705470211029254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/24705470211029254</ArticleId><ArticleId IdType="pmc">PMC8408896</ArticleId><ArticleId IdType="pubmed">34485797</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten A.F.T., Woo E., Yang S., Wang M., Datta D. Unusual Molecular Regulation of Dorsolateral Prefrontal Cortex Layer III Synapses Increases Vulnerability to Genetic and Environmental Insults in Schizophrenia. Biol. Psychiatry. 2022 doi: 10.1016/j.biopsych.2022.02.003. ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2022.02.003</ArticleId><ArticleId IdType="pmc">PMC9372235</ArticleId><ArticleId IdType="pubmed">35305820</ArticleId></ArticleIdList></Reference><Reference><Citation>Newhouse A., Kritzer M.D., Eryilmaz H., Praschan N., Camprodon J.A., Fricchione G., Chemali Z. Neurocircuitry Hypothesis and Clinical Experience in Treating Neuropsychiatric Symptoms of Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2. J. Acad. Consult. Liaison Psychiatry. 2022;63:619&#x2013;627. doi: 10.1016/j.jaclp.2022.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaclp.2022.08.007</ArticleId><ArticleId IdType="pmc">PMC9404079</ArticleId><ArticleId IdType="pubmed">36030055</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizjak D.A., Stangl M., B&#xf6;rner N., B&#xf6;sch F., Durner J., Drunin G., Buhl J.L., Abendroth D. Kynurenine serves as useful biomarker in acute, Long- and Post-COVID-19 diagnostics. Front. Immunol. 2022;13:1004545. doi: 10.3389/fimmu.2022.1004545.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1004545</ArticleId><ArticleId IdType="pmc">PMC9537769</ArticleId><ArticleId IdType="pubmed">36211365</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald B., Flashman L., Saykin A.J. Executive dysfunction following traumatic brain injury: Neural substrates and treatment strategies. NeuroRehabilitation. 2002;17:33&#x2013;44. doi: 10.3233/NRE-2002-17407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/NRE-2002-17407</ArticleId><ArticleId IdType="pubmed">12547981</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllister T.W., Flashman L.A., Sparling M.B., Saykin A.J. Working memory deficits after traumatic brain injury: Catecholaminergic mechanisms and prospects for treatment&#x2014;A review. Brain Inj. 2004;18:331&#x2013;350. doi: 10.1080/02699050310001617370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02699050310001617370</ArticleId><ArticleId IdType="pubmed">14742148</ArticleId></ArticleIdList></Reference><Reference><Citation>Graner J., Oakes T.R., French L.M., Riedy G. Functional MRI in the investigation of blast-related traumatic brain injury. Front. Neurol. 2013;4:16. doi: 10.3389/fneur.2013.00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2013.00016</ArticleId><ArticleId IdType="pmc">PMC3586697</ArticleId><ArticleId IdType="pubmed">23460082</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozga J.E., Povroznik J.M., Engler-Chiurazzi E.B., Vonder Haar C. Executive (dys)function after traumatic brain injury: Special considerations for behavioral pharmacology. Behav. Pharmacol. 2018;29:617&#x2013;637. doi: 10.1097/FBP.0000000000000430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FBP.0000000000000430</ArticleId><ArticleId IdType="pmc">PMC6155367</ArticleId><ArticleId IdType="pubmed">30215621</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoskison M.M., Moore A.N., Hu B., Orsi S.A., Kobori N., Dash P.K. Persistent working memory dysfunction following traumatic brain injury: Evidence for a time-dependent mechanism. Neuroscience. 2009;159:483&#x2013;491. doi: 10.1016/j.neuroscience.2008.12.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.12.050</ArticleId><ArticleId IdType="pmc">PMC4264540</ArticleId><ArticleId IdType="pubmed">19167462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Huynh J., Hylin M.J., O&#x2019;Malley J.J., Perez A., Moore A.N., Dash P.K. Mild Traumatic Brain Injury Reduces Spine Density of Projection Neurons in the Medial Prefrontal Cortex and Impairs Extinction of Contextual Fear Memory. J. Neurotrauma. 2018;35:149&#x2013;156. doi: 10.1089/neu.2016.4898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2016.4898</ArticleId><ArticleId IdType="pmc">PMC5757078</ArticleId><ArticleId IdType="pubmed">28665166</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan X., Zhang J., Shi J., Gong Q., Weng X. Cerebral and functional adaptation with chronic hypoxia exposure: A multi-modal MRI study. Brain Res. 2010;1348:21&#x2013;29. doi: 10.1016/j.brainres.2010.06.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2010.06.024</ArticleId><ArticleId IdType="pubmed">20599837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauser H., Sahu S., Kumar S., Panjwani U. Guanfacine is an effective countermeasure for hypobaric hypoxia-induced cognitive decline. Neuroscience. 2013;254:110&#x2013;119. doi: 10.1016/j.neuroscience.2013.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2013.09.023</ArticleId><ArticleId IdType="pubmed">24056194</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauser H., Sahu S., Panjwani U. Guanfacine promotes neuronal survival in medial prefrontal cortex under hypobaric hypoxia. Brain Res. 2016;1636:152&#x2013;160. doi: 10.1016/j.brainres.2016.01.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2016.01.053</ArticleId><ArticleId IdType="pubmed">26854138</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier S.F., Amat J., Baratta M.V., Paul E., Watkins L.R. Behavioral control, the medial prefrontal cortex, and resilience. Dialogues Clin. Neurosci. 2006;8:397&#x2013;406. doi: 10.31887/DCNS.2006.8.4/smaier.</Citation><ArticleIdList><ArticleId IdType="doi">10.31887/DCNS.2006.8.4/smaier</ArticleId><ArticleId IdType="pmc">PMC3181837</ArticleId><ArticleId IdType="pubmed">17290798</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten A.F.T., Datta D., Wang M. The Genie in the Bottle-Magnified calcium signaling in dorsolateral prefrontal cortex. Mol. Psychiatry. 2021;26:3684&#x2013;3700. doi: 10.1038/s41380-020-00973-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-020-00973-3</ArticleId><ArticleId IdType="pmc">PMC8203737</ArticleId><ArticleId IdType="pubmed">33319854</ArticleId></ArticleIdList></Reference><Reference><Citation>Liston C., McEwen B.S., Casey B.J. Psychosocial stress reversibly disrupts prefrontal processing and attentional control. Proc. Nat. Acad. Sci. USA. 2009;106:912&#x2013;917. doi: 10.1073/pnas.0807041106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0807041106</ArticleId><ArticleId IdType="pmc">PMC2621252</ArticleId><ArticleId IdType="pubmed">19139412</ArticleId></ArticleIdList></Reference><Reference><Citation>Hains A.B., Yabe Y., Arnsten A.F.T. Chronic stimulation of alpha-2A-adrenoceptors with guanfacine protects rodent prefrontal cortex dendritic spines and cognition from the effects of chronic stress. Neurobiol. Stress. 2015;2:1&#x2013;9. doi: 10.1016/j.ynstr.2015.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ynstr.2015.01.001</ArticleId><ArticleId IdType="pmc">PMC4316374</ArticleId><ArticleId IdType="pubmed">25664335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansell E.B., Rando K., Tuit K., Guarnaccia J., Sinha R. Cumulative adversity and smaller gray matter volume in medial prefrontal, anterior cingulate, and insula regions. Biol. Psychiatry. 2012;72:57&#x2013;64. doi: 10.1016/j.biopsych.2011.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2011.11.022</ArticleId><ArticleId IdType="pmc">PMC3391585</ArticleId><ArticleId IdType="pubmed">22218286</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Yang Y., Wang C.J., Gamo N.J., Jin L.E., Mazer J.A., Morrison J.H., Wang X.-J., Arnsten A.F. NMDA receptors subserve working memory persistent neuronal firing In dorsolateral prefrontal cortex. Neuron. 2013;77:736&#x2013;749. doi: 10.1016/j.neuron.2012.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.12.032</ArticleId><ArticleId IdType="pmc">PMC3584418</ArticleId><ArticleId IdType="pubmed">23439125</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Paspalas C.D., Jin L.E., Picciotto M.R., Arnsten A.F.T., Wang M. Nicotinic &#x3b1;7 receptors enhance NMDA cognitive circuits in dorsolateral prefrontal cortex. Proc. Nat. Acad. Sci. USA. 2013;110:12078&#x2013;12083. doi: 10.1073/pnas.1307849110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1307849110</ArticleId><ArticleId IdType="pmc">PMC3718126</ArticleId><ArticleId IdType="pubmed">23818597</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Ramos B., Paspalas C., Shu Y., Simen A., Duque A., Vijayraghavan S., Brennan A., Dudley A.G., Nou E., et al. Alpha2A-adrenoceptor stimulation strengthens working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129:397&#x2013;410. doi: 10.1016/j.cell.2007.03.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.03.015</ArticleId><ArticleId IdType="pubmed">17448997</ArticleId></ArticleIdList></Reference><Reference><Citation>Vornov J.J., Hollinger K.R., Jackson P.F., Wozniak K.M., Farah M.H., Majer P., Rais R., Slusher B.S. Still NAAG&#x2019;ing After All These Years: The Continuing Pursuit of GCPII Inhibitors. Adv. Pharmacol. 2016;76:215&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">27288079</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin L.E., Wang M., Galvin V.C., Lightbourne T.C., Conn P.J., Arnsten A.F.T., Paspalas C.D. mGluR2 vs. mGluR3 in Primate Prefrontal Cortex: Postsynaptic mGluR3 Strengthen Cognitive Networks. Cereb. Cortex. 2018;28:974&#x2013;987. doi: 10.1093/cercor/bhx005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhx005</ArticleId><ArticleId IdType="pmc">PMC5974790</ArticleId><ArticleId IdType="pubmed">28108498</ArticleId></ArticleIdList></Reference><Reference><Citation>Finlay J.M., Zigmond M.J., Abercrombie E.D. Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: Effects of diazepam. Neuroscience. 1995;64:619&#x2013;628. doi: 10.1016/0306-4522(94)00331-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(94)00331-X</ArticleId><ArticleId IdType="pubmed">7715775</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein L.E., Rasmusson A.M., Bunney S.B., Roth R.H. Role of the amygdala in the coordination of behavioral, neuroendocrine and prefrontal cortical monoamine responses to psychological stress in the rat. J. Neurosci. 1996;16:4787&#x2013;4798. doi: 10.1523/JNEUROSCI.16-15-04787.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.16-15-04787.1996</ArticleId><ArticleId IdType="pmc">PMC6579011</ArticleId><ArticleId IdType="pubmed">8764665</ArticleId></ArticleIdList></Reference><Reference><Citation>Zink C., Barker P., Sawa A., Weinberger D., Wang A., Quillian H., Ulrich W., Chen Q., Jaffe A., Kleinman J., et al. Missense Mutation in FOLH1 is Associated with Decreased NAAG Levels and Impaired Working Memory Circuitry and Cognition. Am. J. Psychiatry. 2020;177:1129&#x2013;1139. doi: 10.1176/appi.ajp.2020.19111152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2020.19111152</ArticleId><ArticleId IdType="pubmed">33256444</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Datta D., Woo E., Duque A., Morozov Y.M., Arellano J., Slusher B.S., Wang M., Arnsten A.F.T. Inhibition of glutamate-carboxypeptidase-II in dorsolateral prefrontal cortex: Potential therapeutic target for neuroinflammatory cognitive disorders. Mol. Psychiatry. 2022;27:4252&#x2013;4263. doi: 10.1038/s41380-022-01656-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01656-x</ArticleId><ArticleId IdType="pmc">PMC9718677</ArticleId><ArticleId IdType="pubmed">35732693</ArticleId></ArticleIdList></Reference><Reference><Citation>Liston C., Miller M.M., Goldwater D.S., Radley J.J., Rocher A.B., Hof P.R., Morrison J.H., McEwen B.S. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J. Neurosci. 2006;26:7870&#x2013;7874. doi: 10.1523/JNEUROSCI.1184-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1184-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674229</ArticleId><ArticleId IdType="pubmed">16870732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobori N., Clifton G.L., Dash P.K. Enhanced catecholamine synthesis in the prefrontal cortex after traumatic brain injury: Implications for prefrontal dysfunction. J. Neurotrauma. 2006;23:1094&#x2013;1102. doi: 10.1089/neu.2006.23.1094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2006.23.1094</ArticleId><ArticleId IdType="pubmed">16866622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobori N., Hu B., Dash P.K. Altered adrenergic receptor signaling following traumatic brain injury contributes to working memory dysfunction. Neuroscience. 2011;172:293&#x2013;302. doi: 10.1016/j.neuroscience.2010.10.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2010.10.048</ArticleId><ArticleId IdType="pmc">PMC3010433</ArticleId><ArticleId IdType="pubmed">20974230</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobori N., Moore A.N., Dash P.K. Altered regulation of protein kinase a activity in the medial prefrontal cortex of normal and brain-injured animals actively engaged in a working memory task. J. Neurotrauma. 2015;32:139&#x2013;148. doi: 10.1089/neu.2014.3487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2014.3487</ArticleId><ArticleId IdType="pmc">PMC4291093</ArticleId><ArticleId IdType="pubmed">25027811</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q. Kynurenines in the mammalian brain: When physiology meets pathology. Nat. Rev. Neurosci. 2012;13:465&#x2013;477. doi: 10.1038/nrn3257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3257</ArticleId><ArticleId IdType="pmc">PMC3681811</ArticleId><ArticleId IdType="pubmed">22678511</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan E.B., Frugier T., Lim C.K., Heng B., Sundaram G., Tan M., Rosenfeld J.V., Walker D.W., Guillemin G.J., Morganti-Kossmann M.C. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans. J. Neuroinflamm. 2015;12:110. doi: 10.1186/s12974-015-0328-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0328-2</ArticleId><ArticleId IdType="pmc">PMC4457980</ArticleId><ArticleId IdType="pubmed">26025142</ArticleId></ArticleIdList></Reference><Reference><Citation>Szalardy L., Zadori D., Toldi J., Fulop F., Klivenyi P., Vecsei L. Manipulating kynurenic acid levels in the brain&#x2014;On the edge between neuroprotection and cognitive dysfunction. Curr. Top. Med. Chem. 2012;12:1797&#x2013;1806. doi: 10.2174/1568026611209061797.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568026611209061797</ArticleId><ArticleId IdType="pubmed">23030614</ArticleId></ArticleIdList></Reference><Reference><Citation>Godlewska B.R., Minichino A., Emir U., Angelescu I., Lennox B., Micunovic M., Howes O., Cowen P.J. Brain glutamate concentration in men with early psychosis: A magnetic resonance spectroscopy case-control study at 7&#x2009;T. Transl. Psychiatry. 2021;11:367. doi: 10.1038/s41398-021-01477-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-021-01477-6</ArticleId><ArticleId IdType="pmc">PMC8257573</ArticleId><ArticleId IdType="pubmed">34226485</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon T.D., Chung Y., He G., Sun D., Jacobson A., van Erp T.G., McEwen S., Addington J., Bearden C.E., Cadenhead K., et al. Progressive reduction in cortical thickness as psychosis develops: A multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol. Psychiatry. 2014;77:147&#x2013;157. doi: 10.1016/j.biopsych.2014.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2014.05.023</ArticleId><ArticleId IdType="pmc">PMC4264996</ArticleId><ArticleId IdType="pubmed">25034946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kindler J., Lim C.K., Weickert C.S., Boerrigter D., Galletly C., Liu D., Jacobs K.R., Balzan R., Bruggemann J., O&#x2019;Donnell M., et al. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol. Psychiatry. 2020;25:2860&#x2013;2872. doi: 10.1038/s41380-019-0401-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-019-0401-9</ArticleId><ArticleId IdType="pmc">PMC7577855</ArticleId><ArticleId IdType="pubmed">30940904</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T., Stefanoni D., Reisz J.A., Nemkov T., Bertolone L., Francis R.O., Hudson K.E., Zimring J.C., Hansen K.C., Hod E.A., et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight. 2020;5:e140327. doi: 10.1172/jci.insight.140327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140327</ArticleId><ArticleId IdType="pmc">PMC7453907</ArticleId><ArticleId IdType="pubmed">32559180</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y., Kim D.J., Takahashi T., Broadhurst D.I., Yan H., Ma S., Rattray N.J.W., Casanovas-Massana A., Israelow B., Klein J., et al. Kynurenic acid may underlie sex-specific immune responses to COVID-19. Sci. Signal. 2021;14:eabf8483. doi: 10.1126/scisignal.abf8483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.abf8483</ArticleId><ArticleId IdType="pmc">PMC8432948</ArticleId><ArticleId IdType="pubmed">34230210</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler N.G., Gray N., Kimhofer T., Boughton B., Gay M., Yang R., Morillon A.C., Chin S.T., Ryan M., Begum S., et al. Systemic Perturbations in Amine and Kynurenine Metabolism Associated with Acute SARS-CoV-2 Infection and Inflammatory Cytokine Responses. J. Proteome Res. 2021;20:2796&#x2013;2811. doi: 10.1021/acs.jproteome.1c00052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00052</ArticleId><ArticleId IdType="pubmed">33724837</ArticleId></ArticleIdList></Reference><Reference><Citation>Almulla A.F., Supasitthumrong T., Amrapala A., Tunvirachaisakul C., Jaleel A.K.A., Oxenkrug G., Al-Hakeim H.K., Maes M. The Tryptophan Catabolite or Kynurenine Pathway in Alzheimer&#x2019;s Disease: A Systematic Review and Meta-Analysis. J. Alzheimer&#x2019;s Dis. 2022;88:1325&#x2013;1339. doi: 10.3233/JAD-220295.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-220295</ArticleId><ArticleId IdType="pubmed">35786655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q., Ma W., Song T.Z., Wu Z., Liu Z., Hu Z., Han J.B., Xu L., Zeng B., Wang B., et al. Single-nucleus transcriptomic profiling of multiple organs in a rhesus macaque model of SARS-CoV-2 infection. Zool. Res. 2022;43:1041&#x2013;1062. doi: 10.24272/j.issn.2095-8137.2022.443.</Citation><ArticleIdList><ArticleId IdType="doi">10.24272/j.issn.2095-8137.2022.443</ArticleId><ArticleId IdType="pmc">PMC9700497</ArticleId><ArticleId IdType="pubmed">36349357</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E., Wist J., Masuda R., Lodge S., Nitschke P., Kimhofer T., Loo R.L., Begum S., Boughton B., Yang R., et al. Incomplete Systemic Recovery and Metabolic Phenoreversion in Post-Acute-Phase Nonhospitalized COVID-19 Patients: Implications for Assessment of Post-Acute COVID-19 Syndrome. J. Proteome Res. 2021;20:3315&#x2013;3329. doi: 10.1021/acs.jproteome.1c00224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.1c00224</ArticleId><ArticleId IdType="pubmed">34009992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kucukkarapinar M., Yay-Pence A., Yildiz Y., Buyukkoruk M., Yaz-Aydin G., Deveci-Bulut T.S., Gulbahar O., Senol E., Candansayar S. Psychological outcomes of COVID-19 survivors at sixth months after diagnose: The role of kynurenine pathway metabolites in depression, anxiety, and stress. J. Neural Transm. 2022;129:1077&#x2013;1089. doi: 10.1007/s00702-022-02525-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-022-02525-1</ArticleId><ArticleId IdType="pmc">PMC9261222</ArticleId><ArticleId IdType="pubmed">35796878</ArticleId></ArticleIdList></Reference><Reference><Citation>Chess A.C., Simoni M.K., Alling T.E., Bucci D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull. 2007;33:797&#x2013;804. doi: 10.1093/schbul/sbl033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/schbul/sbl033</ArticleId><ArticleId IdType="pmc">PMC2526148</ArticleId><ArticleId IdType="pubmed">16920787</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander K.S., Wu H.Q., Schwarcz R., Bruno J.P. Acute elevations of brain kynurenic acid impair cognitive flexibility: Normalization by the alpha7 positive modulator galantamine. Psychopharmacology. 2012;220:627&#x2013;637. doi: 10.1007/s00213-011-2539-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00213-011-2539-2</ArticleId><ArticleId IdType="pmc">PMC3666324</ArticleId><ArticleId IdType="pubmed">22038535</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozak R., Campbell B.M., Strick C.A., Horner W., Hoffmann W.E., Kiss T., Chapin D.S., McGinnis D., Abbott A.L., Roberts B.M., et al. Reduction of brain kynurenic acid improves cognitive function. J. Neurosci. 2014;34:10592&#x2013;10602. doi: 10.1523/JNEUROSCI.1107-14.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1107-14.2014</ArticleId><ArticleId IdType="pmc">PMC6802596</ArticleId><ArticleId IdType="pubmed">25100593</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco Ayala T.B., Ram&#xed;rez Ortega D.R., Ovalle Rodr&#xed;guez P.O., Pineda B., P&#xe9;rez de la Cruz G.P., Gonz&#xe1;lez Esquivel D.G., Schwarcz R., Sathyasaikumar K.V., Jim&#xe9;nez Anguiano A.J., P&#xe9;rez de la Cruz V.P. Subchronic N-acetylcysteine Treatment Decreases Brain Kynurenic Acid Levels and Improves Cognitive Performance in Mice. Antioxidants. 2021;10:147. doi: 10.3390/antiox10020147.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10020147</ArticleId><ArticleId IdType="pmc">PMC7909398</ArticleId><ArticleId IdType="pubmed">33498402</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Murakawa Y., Wozniak K.M., Slusher B., Sima A.A. The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J. Neurol. Sci. 2006;247:217&#x2013;223. doi: 10.1016/j.jns.2006.05.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2006.05.052</ArticleId><ArticleId IdType="pubmed">16780883</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahn K.A., Watkins C.C., Alt J., Rais R., Stathis M., Grishkan I., Crainiceau C.M., Pomper M.G., Rojas C., Pletnikov M.V., et al. Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. Proc. Natl. Acad. Sci. USA. 2012;109:20101&#x2013;20106. doi: 10.1073/pnas.1209934109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1209934109</ArticleId><ArticleId IdType="pmc">PMC3523869</ArticleId><ArticleId IdType="pubmed">23169655</ArticleId></ArticleIdList></Reference><Reference><Citation>Rais R., Jiang W., Zhai H., Wozniak K.M., Stathis M., Hollinger K.R., Thomas A.G., Rojas C., Vornov J.J., Marohn M., et al. FOLH1/GCPII is elevated in IBD patients, and its inhibition ameliorates murine IBD abnormalities. JCI Insight. 2016;1:e88634. doi: 10.1172/jci.insight.88634.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.88634</ArticleId><ArticleId IdType="pmc">PMC4985244</ArticleId><ArticleId IdType="pubmed">27536732</ArticleId></ArticleIdList></Reference><Reference><Citation>Arteaga Cabeza O., Zhang Z., Smith Khoury E., Sheldon R.A., Sharma A., Zhang F., Slusher B.S., Kannan R.M., Kannan S., Ferriero D.M. Neuroprotective effects of a dendrimer-based glutamate carboxypeptidase inhibitor on superoxide dismutase transgenic mice after neonatal hypoxic-ischemic brain injury. Neurobiol. Dis. 2021;148:105201. doi: 10.1016/j.nbd.2020.105201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105201</ArticleId><ArticleId IdType="pmc">PMC8351403</ArticleId><ArticleId IdType="pubmed">33271328</ArticleId></ArticleIdList></Reference><Reference><Citation>Neale J.H., Olszewski R. A role for N-acetylaspartylglutamate (NAAG) and mGluR3 in cognition. Neurobiol. Learn. Mem. 2019;158:9&#x2013;13. doi: 10.1016/j.nlm.2019.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2019.01.006</ArticleId><ArticleId IdType="pmc">PMC6397785</ArticleId><ArticleId IdType="pubmed">30630041</ArticleId></ArticleIdList></Reference><Reference><Citation>Datta D., Leslie S.N., Woo E., Amancharla N., Elmansy A., Lepe M., Mecca A.P., Slusher B.S., Nairn A.C., Arnsten A.F.T. Glutamate Carboxypeptidase II in aging rat prefrontal cortex impairs working memory performance. Front. Aging Neurosci. 2021;13:760270. doi: 10.3389/fnagi.2021.760270.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.760270</ArticleId><ArticleId IdType="pmc">PMC8634091</ArticleId><ArticleId IdType="pubmed">34867287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollinger K.R., Sharma A., Tallon C., Lovell L., Thomas A.G., Zhu X., Wiseman R., Wu Y., Kambhampati S.P., Liaw K., et al. Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis. Nanotheranostics. 2022;6:126&#x2013;142. doi: 10.7150/ntno.63158.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ntno.63158</ArticleId><ArticleId IdType="pmc">PMC8671953</ArticleId><ArticleId IdType="pubmed">34976589</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodd S., Dean O., Copolov D.L., Malhi G.S., Berk M. N-acetylcysteine for antioxidant therapy: Pharmacology and clinical utility. Expert. Opin. Biol. Ther. 2008;8:1955&#x2013;1962. doi: 10.1517/14728220802517901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14728220802517901</ArticleId><ArticleId IdType="pubmed">18990082</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y., Peterson P.L., Lee C.P. Effect of N-acetylcysteine on mitochondrial function following traumatic brain injury in rats. J. Neurotrauma. 1999;16:1067&#x2013;1082. doi: 10.1089/neu.1999.16.1067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.1999.16.1067</ArticleId><ArticleId IdType="pubmed">10595823</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitney K., Nikulina E., Rahman S.N., Alexis A., Bergold P.J. Delayed dosing of minocycline plus N-acetylcysteine reduces neurodegeneration in distal brain regions and restores spatial memory after experimental traumatic brain injury. Exp. Neurol. 2021;45:113816. doi: 10.1016/j.expneurol.2021.113816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2021.113816</ArticleId><ArticleId IdType="pmc">PMC8978146</ArticleId><ArticleId IdType="pubmed">34310944</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatti J., Nascimento B., Akhtar U., Rhind S.G., Tien H., Nathens A., da Luz L.T. Systematic Review of Human and Animal Studies Examining the Efficacy and Safety of N-Acetylcysteine (NAC) and N-Acetylcysteine Amide (NACA) in Traumatic Brain Injury: Impact on Neurofunctional Outcome and Biomarkers of Oxidative Stress and Inflammation. Front. Neurol. 2018;8:744. doi: 10.3389/fneur.2017.00744.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00744</ArticleId><ArticleId IdType="pmc">PMC5776005</ArticleId><ArticleId IdType="pubmed">29387038</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcpherson R., Mangram A.J., Barletta J.F., Dzandu J.K. N-Acetylcysteine Is Associated with Reduction Of Post Concussive Symptoms In Elderly Patients: A Pilot Study. J. Trauma Acute Care Surg. 2022 doi: 10.1097/TA.0000000000003639. ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000003639</ArticleId><ArticleId IdType="pubmed">35393384</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominari A., Hathaway I.D., Kapasi A., Paul T., Makkar S.S., Castaneda V., Gara S., Singh B.M., Agadi K., Butt M., et al. Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19. World J. Virol. 2021;10:34&#x2013;52. doi: 10.5501/wjv.v10.i2.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v10.i2.34</ArticleId><ArticleId IdType="pmc">PMC7995409</ArticleId><ArticleId IdType="pubmed">33816149</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Ayala T., Sathyasaikumar K.V., Uys J.D., P&#xe9;rez-de-la-Cruz V., Pidugu L.S., Schwarcz R. N-Acetylcysteine Inhibits Kynurenine Aminotransferase II. Neuroscience. 2020;444:160&#x2013;169. doi: 10.1016/j.neuroscience.2020.07.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2020.07.049</ArticleId><ArticleId IdType="pmc">PMC7484245</ArticleId><ArticleId IdType="pubmed">32768617</ArticleId></ArticleIdList></Reference><Reference><Citation>Biederman J., Melmed R.D., Patel A., McBurnett K., Konow J., Lyne A., Scherer N., SPD503 Study Group A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121:e73&#x2013;e84. doi: 10.1542/peds.2006-3695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-3695</ArticleId><ArticleId IdType="pubmed">18166547</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubia K., Alegr&#xed;a A.A., Brinson H. Brain abnormalities in attention-deficit hyperactivity disorder: A review. Rev. Neurol. 2014;58((Suppl. S1)):S3&#x2013;S16.</Citation><ArticleIdList><ArticleId IdType="pubmed">25252664</ArticleId></ArticleIdList></Reference><Reference><Citation>Ota T., Yamamuro K., Okazaki K., Kishimoto T. Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy. Drug Des. Dev. Ther. 2021;15:1965&#x2013;1969. doi: 10.2147/DDDT.S221126.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S221126</ArticleId><ArticleId IdType="pmc">PMC8123957</ArticleId><ArticleId IdType="pubmed">34007156</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnsten A.F.T., Wang M. The Evolutionary Expansion of mGluR3-NAAG-GCPII Signaling: Relevance to Human Intelligence and Cognitive Disorders. Am. J. Psychiatry. 2020;177:1103&#x2013;1106. doi: 10.1176/appi.ajp.2020.20101458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2020.20101458</ArticleId><ArticleId IdType="pubmed">33256450</ArticleId></ArticleIdList></Reference><Reference><Citation>Gyoneva S., Traynelis S.F. Norepinephrine modulates the motility of resting and activated microglia via different adrenergic receptors. J. Biol. Chem. 2013;288:15291&#x2013;15302. doi: 10.1074/jbc.M113.458901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.458901</ArticleId><ArticleId IdType="pmc">PMC3663549</ArticleId><ArticleId IdType="pubmed">23548902</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Tan S.L., Du J., Chen Y., Jia J., Feng J.G., Liu K.X., Zhou J. Dexmedetomidine alleviates neuroinflammation, restores sleep disorders and neurobehavioral abnormalities in rats with minimal hepatic encephalopathy. Int. Immunopharmacol. 2021;96:107795. doi: 10.1016/j.intimp.2021.107795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107795</ArticleId><ArticleId IdType="pubmed">34162157</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto M., Higuchi H., Honda-Wakasugi Y., Miyake S., Nishioka Y., Yabuki-Kawase A., Maeda S., Miyawaki T. Dexmedetomidine inhibits LPS-induced inflammatory responses through peroxisome proliferator-activated receptor gamma (PPAR&#x3b3;) activation following binding to &#x3b1;2 adrenoceptors. Eur. J. Pharmacol. 2021;892:173733. doi: 10.1016/j.ejphar.2020.173733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173733</ArticleId><ArticleId IdType="pubmed">33220278</ArticleId></ArticleIdList></Reference><Reference><Citation>McAllister T.W., McDonald B.C., Flashman L.A., Ferrell R.B., Tosteson T.D., Yanofsky N.N., Grove M.R., Saykin A.J. Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: Altered working memory and BOLD response. Int. J. Psychophysiol. 2011;82:107&#x2013;114. doi: 10.1016/j.ijpsycho.2011.06.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpsycho.2011.06.022</ArticleId><ArticleId IdType="pmc">PMC3210922</ArticleId><ArticleId IdType="pubmed">21767584</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyoshi T., Mizushima C., Noborio Y., Kimoto Y., Nakaharu Y., Shimamoto S. Efficacy of combination therapy with gabapentin and guanfacine for paroxysmal sympathetic hyperactivity following hypoxic encephalopathy: A case report. J. Int. Med. Res. 2021;49:3000605211009721. doi: 10.1177/03000605211009721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/03000605211009721</ArticleId><ArticleId IdType="pmc">PMC8829780</ArticleId><ArticleId IdType="pubmed">33900871</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor D.F., Grasso D.J., Slivinsky M.D., Pearson G.S., Banga A. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents. J. Child Adolesc. Psychopharmacol. 2013;23:244&#x2013;251. doi: 10.1089/cap.2012.0119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cap.2012.0119</ArticleId><ArticleId IdType="pmc">PMC3657282</ArticleId><ArticleId IdType="pubmed">23683139</ArticleId></ArticleIdList></Reference><Reference><Citation>Fesharaki-Zadeh A., Lowe N., Arnsten A.F. Clinical experience with the &#x3b1;2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in &#x201c;Long-COVID19&#x201d;. Neuroimmunol. Rep. 2023;3:100154. doi: 10.1016/j.nerep.2022.100154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nerep.2022.100154</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>